- Home
- CROX vs TFX Comparison
CROX vs TFX Comparison
Compare CROX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- TFX
- Stock Information
- Founded
- CROX 1999
- TFX 1943
- Country
- CROX United States
- TFX United States
- Employees
- CROX N/A
- TFX N/A
- Industry
- CROX Shoe Manufacturing
- TFX Medical/Dental Instruments
- Sector
- CROX Consumer Discretionary
- TFX Health Care
- Exchange
- CROX Nasdaq
- TFX Nasdaq
- Market Cap
- CROX 8.3B
- TFX 8.3B
- IPO Year
- CROX 2006
- TFX N/A
- Fundamental
- Price
- CROX $107.60
- TFX $175.43
- Analyst Decision
- CROX Buy
- TFX Buy
- Analyst Count
- CROX 14
- TFX 7
- Target Price
- CROX $140.62
- TFX $252.50
- AVG Volume (30 Days)
- CROX 2.0M
- TFX 498.9K
- Earning Date
- CROX 02-13-2025
- TFX 02-27-2025
- Dividend Yield
- CROX N/A
- TFX 0.77%
- EPS Growth
- CROX 24.16
- TFX N/A
- EPS
- CROX 15.88
- TFX 5.03
- Revenue
- CROX $4,102,108,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- CROX $3.87
- TFX $4.56
- Revenue Next Year
- CROX $4.11
- TFX $4.63
- P/E Ratio
- CROX $6.78
- TFX $34.93
- Revenue Growth
- CROX 3.53
- TFX 2.27
- 52 Week Low
- CROX $88.25
- TFX $165.62
- 52 Week High
- CROX $165.32
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- CROX 55.83
- TFX 50.59
- Support Level
- CROX $104.66
- TFX $165.62
- Resistance Level
- CROX $111.15
- TFX $176.71
- Average True Range (ATR)
- CROX 3.99
- TFX 3.46
- MACD
- CROX 1.82
- TFX 0.50
- Stochastic Oscillator
- CROX 82.76
- TFX 70.58
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include the Americas, Asia Pacific, and EMEA.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.